

2. Cash dividends

	Annual dividends per share				
	First quarter-end	Second quarter-end	Third quarter-end	Fiscal year-end	Total
	Yen	Yen	Yen	Yen	Yen
Fiscal year ended March 31, 2025	-	50.00	-	50.00	100.00
Fiscal year ending March 31, 2026	-	50.00	-		
Fiscal year ending March 31, 2026 (Forecast)				50.00	100.00

Note: Revisions to the forecast of cash dividends most recently announced: None

3. Consolidated financial result forecasts for the fiscal year ending March 31, 2026 (from April 1, 2025 to March 31, 2026)

(Percentages indicate year-on-year changes.)

	Net sales		Operating profit		Ordinary profit		Profit attributable to owners of parent		Basic earnings per share
	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%	Yen
Full year	2,468,000	2.8	33,600	(9.5)	35,100	(9.6)	32,800	(4.9)	455.13

Note: Revisions to the financial result forecast most recently announced: None

*The average number of shares outstanding during the period used to calculate basic earnings per share does not reflect the impact of the share repurchase announced, on May 13, 2025, in the release titled "Suzuken Announces Share Repurchase Program."

* Notes

(1) Significant changes in the scope of consolidation during the period: None

Newly included: - companies ()
 Excluded: - companies ()

(2) Adoption of accounting treatment specific to the preparation of quarterly consolidated financial statements: None

(3) Changes in accounting policies, changes in accounting estimates, and restatement

- (i) Changes in accounting policies due to revisions to accounting standards and other regulations: None
- (ii) Changes in accounting policies due to other reasons: None
- (iii) Changes in accounting estimates: None
- (iv) Restatement: None

(4) Number of issued shares (common shares)

(i) Total number of issued shares at the end of the period (including treasury shares)

As of December 31, 2025	72,167,204 shares
As of March 31, 2025	72,167,204 shares

(ii) Number of treasury shares at the end of the period

As of December 31, 2025	3,646,064 shares
As of March 31, 2025	100,049 shares

(iii) Average number of shares outstanding during the period (cumulative from the beginning of the fiscal year)

Nine months ended December 31, 2025	70,529,342 shares
Nine months ended December 31, 2024	76,981,069 shares

* Review of the Japanese-language originals of the attached consolidated quarterly financial statements by certified public accountants or an audit firm: Yes (voluntary)

* Proper use of earnings forecasts, and other special matters

Earnings forecasts and other statements about the future that are included in this material are based on information currently in the possession of the Company, and certain conditions judged reasonable by the Company. These statements do not guarantee that the Company will achieve its earnings forecasts. In addition, actual results, etc., may differ significantly due to various factors. For notes, etc., on the conditions for earnings forecasts and the use of earnings forecasts, please refer to "1. Overview of Operating Results (3) Explanation of Forecasts of Consolidated Financial Results and Other Forward-Looking Statements" on page 6 of the attached documentation.

○ Contents of Attached Documentation

1. Overview of Operating Results.....	2
(1) Overview of Operating Results for the Third Quarter of the Fiscal Year	2
(2) Overview of Financial Condition for the Third Quarter of the Fiscal Year	6
(3) Explanation of Forecasts of Consolidated Financial Results and Other Forward-Looking Statements.....	6
2. Quarterly Consolidated Financial Statements and Key Notes	7
(1) Quarterly Consolidated Balance Sheets	7
(2) Quarterly Consolidated Statements of Income and Consolidated Statements of Comprehensive Income ...	9
Quarterly Consolidated Statements of Income.....	9
Third quarter consolidated accounting period.....	9
Quarterly Consolidated Statements of Comprehensive Income	10
Third quarter consolidated accounting period.....	10
(3) Notes on Quarterly Consolidated Financial Statements.....	11
<Significant Matters for Preparation of Quarterly Consolidated Financial Statements>	11
<Notes on Segment Information etc.>.....	11
<Notes to any Significant Changes in the Amount of Shareholders' Equity>	13
<Notes on the Assumption of the Company as a Going Concern>	13
<Notes on Quarterly Consolidated Cash Flow Statements>	13

1. Overview of Operating Results

(1) Overview of Operating Results for the Third Quarter of the Fiscal Year

During the nine months ended December 31, 2025, we saw continued currency market fluctuations and inflation reflecting rising prices of electrical power, energy, and raw materials for multiple reasons, including uncertainties about the policy trends of the US administration. Furthermore, alongside the policy-driven wage hikes, the increasing labor shortages, symbolized by the so-called “2024 Problem,” have led to rising costs across various areas. Meanwhile, with uncertainty surrounding the ability to pass on these costs through price increases, the outlook for the domestic economy and corporate earnings has continued to remain unclear.

Under these circumstances, the Suzuken Group has formulated a medium-term management plan that concludes with the current fiscal year. Through the implementation of this medium-term management plan, the Group will carry out its transformation into a health creation enterprise working as “One Team” and will create new value as an entity that continues to provide new solutions and hope for the changing healthcare ecosystem, thereby further enhancing corporate value and contributing to solving social issues. This medium-term management plan positions “Reform of existing businesses” and “Preparation for new growth businesses” as our main focuses in the lead-up to the 100th anniversary in 2032.

During the nine months ended December 31, 2025, we worked on several measures as part of “Reform of existing businesses.” Such measures included the reinforcement of our distribution model for specialty drugs including orphan drugs and regenerative medicine products through collaboration with various companies, and the creation of a new profit model through MS*¹ activities.

Specifically, in order to build a healthcare distribution platform, we are working on enhancing the quality of our pharmaceutical distribution by implementing the specialty drug traceability solution Cubixx® in regional core hospitals and other medical institutions nationwide. In the distribution of specialty drugs, we have strived to meet the requirements of pharmaceutical companies aiming for market entry and new product launches in Japan and strengthened our distribution base to ensure reliable delivery of new drugs to patients awaiting treatment.

Additionally, as a program aimed at allowing real-time visualization and optimization of pharmaceutical distribution, we have developed and introduced systems that help reduce the workloads of medical institutions and pharmacies through pharmaceutical shipping adjustments and improve productivity at our company. In May 2023, we introduced the Delivery Schedule Notification Service and the Delivery Schedule Notification app which allow the delivery dates of ordered pharmaceuticals, inventory of substitute products, and other information to be checked on the internet. They are already in use by over approximately 103,000 customers (number registered as of the end of December 2025). In addition, we have introduced the Order Proposal app in October 2023, to provide ordering support based on demand forecasts, which is in use by over approximately 19,000 customers (number registered as of the end of December 2025).

Taking the “2024 Problem” into account, we established the Greater Tokyo Distribution Center in Soka City, Saitama Prefecture, and commenced full operations in April 2024. It is the industry’s first complex distribution center that incorporates a contract manufacturing and manufacturer logistics area within a wholesale logistics hub, employing cutting-edge robotic technology for enhanced automation and labor efficiency. Additionally, in May 2025, we entered into a land sale agreement with Kasugai City in Aichi Prefecture and acquired land for the development of a new logistics hub, tentatively named the Chubu Distribution Center, to serve the Chubu region (central Japan) (with construction scheduled to start in October 2027). In the future, we aim to achieve a variety of benefits, including improved efficiency through automation, reduced transportation and delivery costs, quality assurance that complies with GDP*² standards, environmental benefits such as reduced CO₂ emissions, and further strengthening our BCP response in the event of a disaster by maximizing the use of the Group’s distribution network, starting with both the Greater Tokyo Distribution Center and Chubu Distribution Center.

Moving forward, the Suzuken Group will continue to enhance its logistics infrastructure to ensure a stable supply.

For “Preparation for new growth businesses,” the Suzuken Group has been working with its partner companies to establish new distribution channels, accelerate the development of the digital health business through collaborations, and advance innovative services and information businesses, in order to provide new value to pharmaceutical companies, medical institutions, pharmacies, and patients.

Specifically, we have been offering services through the COLLABO Portal*³, a portal site for medical and nursing care professionals. In addition to distributing various services and information owned by the Suzuken Group, the COLLABO Portal is equipped with functions that connect customers with the Suzuken Group, pharmaceutical companies, and healthcare professionals and specialist staff, as well as functions that deliver digital health services

from cooperating companies in an integrated manner. Our focus is to create an environment in which medical and nursing care facilities can use digital health services safely and securely.

By linking COLLABO Portal with “Medical Care Station (MCS)^{*4}”, a social healthcare collaboration platform specialized in medical and nursing care deployed by Embrace Co., Ltd., our wholly owned subsidiary, we have established a new connection between the Company and over 410,000 medical and nursing care professionals (on a registered accounts basis). Moving forward, we will accelerate our efforts to develop a new information-driven revenue business, including marketing support that leverages our existing connections with approximately 160,000 customers in our pharmaceutical wholesale business nationwide and the newly built connections with over 410,000 individual medical and nursing care professionals.

In November 2025, Collabo Square Co., Ltd., which builds and operates a healthcare platform that provides safe, reliable, and highly convenient digital services, including COLLABO Portal, together with the Healthcare AI Platform Collaborative Innovation Partnership (HAIP)^{*5}, an organization authorized by the Ministry of Health, Labour and Welfare and the Ministry of Economy, Trade and Industry, and AIHOBS Inc.^{*6}, signed a Memorandum of Understanding to promote the use of generative AI in the medical and nursing care sectors. Moving forward, the three parties will strive to reduce the operational burden on medical and nursing care professionals in utilizing digital transformation services and to develop a secure and trusted framework that enables the safe and confident use of AI technologies, such as generative AI, and services offered by SaaS providers.

Furthermore, starting September 2025, in order to further accelerate initiatives based on the concept of “Strategic recombination of capabilities”—aimed at combining the capabilities of the Group and its partner companies—we relocated the offices of Suzuken’s headquarters departments and Group companies in Tokyo (six companies including the Company; approximately 200 employees) to the MSH Nihonbashi Hakozaiki Building. By consolidating these functions, we aim to strengthen collaboration among headquarters and business units, including partner companies, and promote group-wide integrated management with a “One Team” approach.

The Suzuken Group, in collaboration with health-tech companies and other external partners, will continue to accelerate its efforts towards transforming into a health creation enterprise.

As part of risk management measures, we established the Information Security Practices Committee on April 1, 2025 as a practices committee under the Risk Management and Compliance Committee, which works under the Board of Directors. Behind this was a growing need to address increasingly sophisticated and serious information security risks as witnessed in a large number of incidents such as ransomware. Through the Information Security Practices Committee, we will further promote the grasping, management, and enhancement of the security level of the Group centrally.

Regarding our shareholder return policy, we revised and strengthened the policy disclosed in May 2023 on November 10, 2023. Our policy is based on the continuation of stable dividends, with a commitment to achieve shareholder returns exceeding a total return ratio of 100% over the three-year average up to the fiscal year ending March 2026, the final year of our medium-term management plan, aiming to enhance shareholder returns. Additionally, through investment in strengthening our existing businesses and creating new ventures, we aim to improve our corporate value and capital efficiency. In line with the above policy, at the Board of Directors meeting held on May 13, 2025, we resolved to repurchase shares pursuant to the provisions of our Articles of Incorporation in accordance with the provisions of Article 459, Paragraph 1 of the Companies Act. As of the end of December 2025, we have repurchased approximately 3,570,000 shares (total amount of repurchase: ¥20,385 million).

<Details of the Share Repurchase>

Class of shares to be repurchased:	Common shares
Total number of shares to be repurchased:	Up to 5,200,000 shares
Total amount of repurchase:	Up to ¥26,000 million
Period of repurchase:	May 15, 2025 to March 19, 2026
Method of repurchase:	Market purchases on the Tokyo Stock Exchange including purchases through the Off-Auction Own Share Repurchase Trading System (ToSTNeT-3)

Our consolidated business results for the nine months ended December 31, 2025, showed an increase in net sales due to growth in the ethical drug market and contributions from new drugs, including specialty drugs, despite a year-on-year decrease in sales of COVID-19-related products (including therapeutic and diagnostic agents, etc.). In terms of profits, we continued efforts to ensure appropriate levels of profitability and to review and control selling, general,

and administrative expenses. However, both operating profit and ordinary profit decreased due to an increase in operating expenses caused by inflationary trends, including higher outsourcing costs, in addition to rising procurement costs for pharmaceuticals and other items. Meanwhile, profit attributable to owners of parent increased, reflecting the reduction of four cross-held securities and the recognition of ¥14,900 million in gains on the sale of investment securities, recorded under extraordinary income.

As a result, net sales were ¥1,885,630 million (up 2.6% year on year), operating profit was ¥27,230 million (down 8.6% year on year), ordinary profit was ¥29,315 million (down 5.2% year on year), and profit attributable to owners of parent was ¥31,014 million (up 1.1% year on year).

***1 MS (Marketing Specialist)**

: This refers to a person responsible for sales in the pharmaceutical distribution business.

An MS visits places such as medical institutions and pharmacies to introduce drugs, conduct business negotiations, and provide and collect information.

***2 GDP (Good Distribution Practice)**

: This refers to the standards for the proper distribution of pharmaceuticals.

The purpose of GDP is to ensure the management of distribution channels in the pharmaceutical market, maintain the integrity of pharmaceuticals, and prevent the infiltration of counterfeit drugs into the regular distribution channels.

***3 COLLABO Portal**

: This refers to a comprehensive portal site operated by our wholly owned subsidiary, Collabo Square. The portal provides convenient one-stop digital health services including solutions functions that provide a variety of services operated by the Suzuken Group, communications functions that enable the Suzuken Group MSs, MRs, and specialized staff to make points of contact with customers remotely by utilizing chat, video, and other functions, and the purchasing functions which are linked with Amazon Business as well as other functions. The portal also contributes to more efficient operations at medical and nursing care workplaces by utilizing SSO (Single Sign-On: a mechanism that allows multiple systems to be used based on a single user authentication) and data integration, and by increasing accessibility.

***4 Medical Care Station (MCS)**

: This refers to a private timeline-based social networking service (SNS) for medical and nursing care collaboration. It is user-friendly and is compatible with a variety of devices including tablets, smartphones, and computers. With robust security measures, it allows easy access and sharing of necessary information not only within hospitals and facilities but also from outside locations. It facilitates comprehensive community care and interprofessional work by connecting doctors and allied health professionals, nursing care workers, patients, and their families across different professions and roles.

***5 Healthcare AI Platform Collaborative Innovation Partnership (HAIP)**

: This refers to a Collaborative Innovation Partnership established on April 1, 2021, as a non-profit corporation under the Research and Development Partnership Act, with the approval of the Minister of Health, Labour and Welfare and the Minister of Economy, Trade and Industry. HAIP aims to bring together many companies, academic institutions, and medical organizations involved in healthcare to address problems in the adoption and development of medical AI services that individual organizations alone cannot solve.

***6 AIHOBS Inc.**

: This refers to a business entity established by HAIP on April 11, 2025, with the goal of implementing research outcomes into society.

It offers a platform service that enables medical institutions and nursing care facilities to utilize medical digital transformation services and medical AI services easily and securely within a protected network environment. By connecting service providers who develop and deliver various solution services using technologies, such as imaging AI and generative AI, with medical institutions, AIHOBS is committed to realizing next-generation healthcare where medical digital transformation and AI can be used safely and securely.

Operating results by segment were as follows:

(Millions of yen)

Name of business segment		Nine months ended December 31, 2024	Nine months ended December 31, 2025	Change (%)
Pharmaceutical Distribution	Net sales	1,774,851	1,822,209	2.7
	Operating profit	25,195	22,792	(9.5)
Healthcare Product Development	Net sales	40,617	39,335	(3.2)
	Operating profit	2,465	1,776	(28.0)
Community Healthcare and Nursing Care Support	Net sales	70,961	70,418	(0.8)
	Operating profit	631	792	25.6
Specialty Drug Contract Distribution	Net sales	225,202	326,186	44.8
	Operating profit	639	871	36.3
Healthcare-Related Services	Net sales	31,941	32,036	0.3
	Operating profit	831	929	11.7

(Note) Segment sales results include intersegment transactions.

(Pharmaceutical Distribution)

The growth of the ethical drug market is presumed to be due to the expansion of the oncology drug market and the contributions from new drugs, including specialty drugs.

Under these circumstances, segment net sales were ¥1,822,209 million (up 2.7% year on year) due to contributions of new drugs, including specialty drugs, and the growth of the ethical drug market, despite a year-on-year decrease in sales of COVID-19-related products (including therapeutic and diagnostic agents, etc.). Operating profit was ¥22,792 million (down 9.5% year on year) due to factors including an increase in operating expenses caused by inflationary trends, including higher outsourcing costs, in addition to rising procurement costs for pharmaceuticals and other items.

(Healthcare Product Development)

Segment net sales decreased due to the impact of drug price revisions, etc., despite growth in the pharmaceutical manufacturing division from UPASITA IV Injection Syringe for Dialysis (medical treatment for secondary hyperparathyroidism) and Darbepoetin Alfa BS Syringe for Injection (a long-acting erythropoiesis-stimulating agent). Operating profit decreased due to factors including a decline in revenue and an increase in research and development expenses resulting from progress in development.

As a result of the above, net sales were ¥39,335 million (down 3.2% year on year), and operating profit was ¥1,776 million (down 28.0% year on year).

(Community Healthcare and Nursing Care Support)

Segment net sales decreased slightly due to a decrease in revenue in the pharmacy division, which was affected by a reduced number of operating pharmacy stores following closures, leading to fewer prescriptions processed. Operating profit increased as a result of efforts to optimize selling, general and administrative expenses.

As a result of the above, net sales were ¥70,418 million (down 0.8% year on year), and operating profit was ¥792 million (up 25.6% year on year).

(Specialty Drug Contract Distribution^{*7})

Segment net sales increased significantly due to factors including growth in the market for existing contracted pharmaceuticals and an increase in newly contracted pharmaceuticals. Operating profit also increased due to higher revenue.

As a result of the above, net sales were ¥326,186 million (up 44.8% year on year), and operating profit was ¥871 million (up 36.3% year on year).

^{*7} Specialty Drug Contract Distribution Business

: This refers to a business where we contract distribution of pharmaceutical products including orphan drugs that requires stricter quality control and distribution management compared to the typical distribution channels, from manufacturers. Most of the net sales in the Specialty Drug Contract Distribution Business are generated from internal transactions with the Pharmaceutical Distribution Business, as actual distribution operations

including sales and delivery to medical institutions are carried out by our Pharmaceutical Distribution Business.

(Healthcare-Related Services)

Segment net sales increased due to factors including growth in contracts in the logistics services for pharmaceutical manufacturers in the external logistics division. Operating profit increased partly due to profitability improvement in the digital health division.

As a result of the above, net sales were ¥32,036 million (up 0.3% year on year), and operating profit was ¥929 million (up 11.7% year on year).

(2) Overview of Financial Condition for the Third Quarter of the Fiscal Year

Assets, liabilities, and net assets at the end of the third quarter consolidated accounting period were as follows:

(Assets)

Total assets as of December 31, 2025 increased by ¥193,632 million from March 31, 2025 to reach ¥1,307,463 million. The main factors of this increase were as follows:

Current assets increased by ¥199,927 million from March 31, 2025. This was mainly due to increases of ¥92,065 million in cash and deposits and ¥91,890 million in notes and accounts receivable - trade, despite a decrease of ¥14,946 million in securities.

Non-current assets decreased by ¥6,294 million from March 31, 2025. This was mainly due to decreases of ¥471 million in intangible assets and ¥11,342 million in investments and other assets, despite an increase of ¥5,519 million in property, plant and equipment.

(Liabilities)

Total liabilities as of December 31, 2025 increased by ¥195,843 million from March 31, 2025 to reach ¥902,254 million. This was mainly due to increases of ¥191,915 million in notes and accounts payable - trade and ¥16,665 million in "Other" under "Current liabilities," despite decreases of ¥3,999 million in income taxes payable, ¥3,781 million in provision for bonuses, and ¥1,408 million in provision for loss on Anti-Monopoly Act.

(Net assets)

Total net assets as of December 31, 2025 decreased by ¥2,211 million from March 31, 2025 to reach ¥405,209 million. The main factors of this decrease were as follows:

Shareholders' equity increased by ¥3,686 million from March 31, 2025. This was mainly due to the posting of ¥31,014 million in profit attributable to owners of parent, despite the payment of ¥7,098 million in dividends of surplus and a decrease of ¥20,388 million due to purchase of treasury shares.

Accumulated other comprehensive income decreased by ¥5,903 million from March 31, 2025. This was mainly due to a decrease of ¥5,547 million in valuation difference on available-for-sale securities.

(3) Explanation of Forecasts of Consolidated Financial Results and Other Forward-Looking Statements

With regard to the forecasts of consolidated financial results, there have been no changes to the figures announced on May 13, 2025.

2. Quarterly Consolidated Financial Statements and Key Notes

(1) Quarterly Consolidated Balance Sheets

(Millions of yen)

	As of March 31, 2025	As of December 31, 2025
Assets		
Current assets		
Cash and deposits	102,655	194,720
Notes and accounts receivable - trade	524,134	616,024
Securities	38,927	23,980
Merchandise and finished goods	146,668	172,448
Work in process	1,470	1,882
Raw materials and supplies	5,052	6,000
Other	26,387	29,773
Allowance for doubtful accounts	(1,197)	(805)
Total current assets	844,099	1,044,026
Non-current assets		
Property, plant and equipment	133,512	139,031
Intangible assets		
Goodwill	14	5
Other	12,094	11,631
Total intangible assets	12,108	11,637
Investments and other assets		
Investment securities	84,399	73,096
Other	40,472	40,717
Allowance for doubtful accounts	(760)	(1,045)
Total investments and other assets	124,111	112,768
Total non-current assets	269,732	263,437
Total assets	1,113,831	1,307,463

(Millions of yen)

	As of March 31, 2025	As of December 31, 2025
Liabilities		
Current liabilities		
Notes and accounts payable - trade	635,752	827,668
Income taxes payable	9,949	5,949
Provision for bonuses	9,293	5,511
Provision for loss on Anti-Monopoly Act	3,090	1,681
Other	21,028	37,694
Total current liabilities	679,114	878,506
Non-current liabilities		
Retirement benefit liability	2,186	2,156
Other	25,110	21,590
Total non-current liabilities	27,296	23,747
Total liabilities	706,410	902,254
Net assets		
Shareholders' equity		
Share capital	13,546	13,546
Capital surplus	32,147	32,147
Retained earnings	332,375	356,291
Treasury shares	(499)	(20,729)
Total shareholders' equity	377,569	381,255
Accumulated other comprehensive income		
Valuation difference on available-for-sale securities	32,773	27,225
Revaluation reserve for land	(4,803)	(4,803)
Foreign currency translation adjustment	2,365	2,006
Remeasurements of defined benefit plans	(613)	(609)
Total accumulated other comprehensive income	29,722	23,819
Non-controlling interests	128	133
Total net assets	407,420	405,209
Total liabilities and net assets	1,113,831	1,307,463

(2) Quarterly Consolidated Statements of Income and Consolidated Statements of Comprehensive Income

Quarterly Consolidated Statements of Income

Third quarter consolidated accounting period

(Millions of yen)

	For the nine months ended December 31, 2024	For the nine months ended December 31, 2025
Net sales	1,838,670	1,885,630
Cost of sales	1,691,958	1,741,039
Gross profit	146,711	144,590
Selling, general and administrative expenses	116,912	117,360
Operating profit	29,799	27,230
Non-operating income		
Interest income	145	118
Dividend income	1,163	1,195
Share of profit of entities accounted for using equity method	-	273
Rental income from real estate	218	213
Other	727	580
Total non-operating income	2,255	2,381
Non-operating expenses		
Interest expenses	29	32
Share of loss of entities accounted for using equity method	798	-
Rental expenses on real estate	181	186
Other	130	77
Total non-operating expenses	1,140	296
Ordinary profit	30,914	29,315
Extraordinary income		
Gain on sale of non-current assets	141	159
Gain on sale of investment securities	10,906	14,951
Other	1,957	121
Total extraordinary income	13,005	15,233
Extraordinary losses		
Loss on sale and retirement of non-current assets	86	204
Loss on sale of investment securities	-	59
Loss on valuation of investment securities	3	16
Other	30	8
Total extraordinary losses	121	288
Profit before income taxes	43,798	44,260
Income taxes	13,121	13,240
Profit	30,677	31,020
Profit attributable to non-controlling interests	4	5
Profit attributable to owners of parent	30,672	31,014

Quarterly Consolidated Statements of Comprehensive Income

Third quarter consolidated accounting period

(Millions of yen)

	For the nine months ended December 31, 2024	For the nine months ended December 31, 2025
Profit	30,677	31,020
Other comprehensive income		
Valuation difference on available-for-sale securities	(2,997)	(5,515)
Foreign currency translation adjustment	(17)	(20)
Remeasurements of defined benefit plans, net of tax	(292)	1
Share of other comprehensive income of entities accounted for using equity method	114	(367)
Total other comprehensive income	(3,193)	(5,903)
Comprehensive income	27,483	25,116
Comprehensive income attributable to		
Comprehensive income attributable to owners of parent	27,478	25,111
Comprehensive income attributable to non-controlling interests	4	5

(3) Notes on Quarterly Consolidated Financial Statements

<Significant Matters for Preparation of Quarterly Consolidated Financial Statements>

Our quarterly consolidated financial statements have been prepared in accordance with Article 4, Paragraph 1 of the Practical Policy Concerning the Preparation of Quarterly Financial Statements, etc. issued by the Tokyo Stock Exchange, Inc., the Nagoya Stock Exchange, Inc., and the Sapporo Securities Exchange, as well as the accounting standards for quarterly financial statements that are generally accepted as fair and appropriate in Japan. However, certain disclosures have been omitted as stipulated in Article 4, Paragraph 2 of the Practical Policy Concerning the Preparation of Quarterly Financial Statements, etc.

<Notes on Segment Information etc.>

Nine months ended December 31, 2024 (From April 1, 2024 to December 31, 2024)

1. Information on sales, income and loss classified by reporting segment

(Millions of yen)

	Reporting segment					Total
	Pharmaceutical Distribution	Healthcare Product Development	Community Healthcare and Nursing Care Support	Specialty Drug Contract Distribution	Healthcare-Related Services	
Net sales						
Sales to external customers	1,735,281	9,147	70,954	4,954	18,332	1,838,670
Intersegment sales and transactions	39,570	31,470	7	220,248	13,609	304,904
Total	1,774,851	40,617	70,961	225,202	31,941	2,143,575
Segment income	25,195	2,465	631	639	831	29,763

2. Reconciliation of reporting segments totals to quarterly consolidated statements of income/(loss) amounts and main components of reconciliation

(Matters concerning reconciliation)

(Millions of yen)

Income	Value
Reporting segment total	29,763
Elimination of intersegment transactions	35
Operating profit on the consolidated financial statements	29,799

3. Information on impairment loss on non-current assets and goodwill by reporting segment

(Significant Impairment Loss on Non-Current Assets)

N/A

(Significant Changes in the Amount of Goodwill)

N/A

(Significant Gain on Negative Goodwill)

N/A

Nine months ended December 31, 2025 (From April 1, 2025 to December 31, 2025)

1. Information on sales, income and loss classified by reporting segment

(Millions of yen)

	Reporting segment					Total
	Pharmaceutical Distribution	Healthcare Product Development	Community Healthcare and Nursing Care Support	Specialty Drug Contract Distribution	Healthcare-Related Services	
Net sales						
Sales to external customers	1,782,110	8,950	70,413	5,311	18,844	1,885,630
Intersegment sales and transactions	40,099	30,385	4	320,874	13,191	404,555
Total	1,822,209	39,335	70,418	326,186	32,036	2,290,185
Segment income	22,792	1,776	792	871	929	27,161

2. Reconciliation of reporting segments totals to quarterly consolidated statements of income/(loss) amounts and main components of reconciliation

(Matters concerning reconciliation)

(Millions of yen)

Income	Value
Reporting segment total	27,161
Elimination of intersegment transactions	68
Operating profit on the consolidated financial statements	27,230

3. Matters concerning changes to reporting segments

Effective from the previous fiscal year, we have changed to a method that presents the Specialty Drug Contract Distribution Business as a new reporting segment, which was previously included in the Healthcare-Related Services Business segment, due to the increased quantitative materiality of the business.

Note that the segment information of nine months ended December 31, 2024 was created using the categories after the change.

4. Information on impairment loss on non-current assets and goodwill by reporting segment

(Significant Impairment Loss on Non-Current Assets)

N/A

(Significant Changes in the Amount of Goodwill)

N/A

(Significant Gain on Negative Goodwill)

N/A

<Notes to any Significant Changes in the Amount of Shareholders' Equity>

Based on a resolution from the Board of Directors meeting held on May 13, 2025, we repurchased 3,575,600 shares (acquisition price of ¥20,385 million) during the third quarter consolidated accounting period ended December 31, 2025.

Primarily for the reason mentioned above, our treasury shares amounted to ¥20,729 million as of December 31, 2025.

<Notes on the Assumption of the Company as a Going Concern>

N/A

<Notes on Quarterly Consolidated Cash Flow Statements>

The quarterly consolidated statement of cash flows for the cumulative third quarter of the current fiscal year has not been prepared.

However, depreciation and amortization expenses (including amortization expenses related to intangible assets, excluding goodwill) and the amortization amount of goodwill for the cumulative third quarter are as follows:

	(Millions of yen)	
	Nine months ended December 31, 2024	Nine months ended December 31, 2025
Depreciation and amortization	8,902	9,158
Amortization of goodwill	8	8